Meridian Bioscience (NASDAQ:VIVO) Earning Somewhat Favorable News Coverage, Analysis Shows
Press coverage about Meridian Bioscience (NASDAQ:VIVO) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Meridian Bioscience earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.442739685915 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Cell Based Assays Market: Future Market Projections for Forthcoming Years (canadianbusinesstribune.com)
- INNT Soars, CDXS Sees 20% Growth, So Long CGNT, Mark Your Calendar For ASMB (markets.businessinsider.com)
- Campylobacter Diagnostics Market Value Projected to Expand by 2025 (openpr.com)
- Meridian Bioscience (VIVO) Raised to “Hold” at BidaskClub (americanbankingnews.com)
A number of analysts have recently commented on VIVO shares. Canaccord Genuity upped their price target on Meridian Bioscience from $14.00 to $16.00 and gave the company a “hold” rating in a research note on Friday, January 26th. Zacks Investment Research cut Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Sunday, January 21st. Finally, BidaskClub raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, January 25th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The company had revenue of $52.30 million during the quarter, compared to analysts’ expectations of $49.00 million. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. Meridian Bioscience’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.15 EPS. sell-side analysts predict that Meridian Bioscience will post 0.72 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 15th. Investors of record on Monday, February 5th were paid a dividend of $0.125 per share. The ex-dividend date was Friday, February 2nd. This represents a $0.50 dividend on an annualized basis and a yield of 3.36%. Meridian Bioscience’s payout ratio is 98.04%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.mareainformativa.com/2018/03/16/meridian-bioscience-vivo-given-daily-media-impact-rating-of-0-09-updated-updated-updated.html.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.